Because of the favourable safety and tolerability profiles of atazanavir (ATV) and raltegravir (RAL), attention has recently turned to the use of dual ATV plus RAL therapy as a nucleoside reverse transcriptase inhibitor- sparing treatment strategy in highly antiretroviral treatment (ART)-experienced HIV-infected patients.
Methods
A retrospective observational study was carried out to assess the maintenance of viral suppression and ART tolerability in 20 highly ART-experienced patients with viral suppression, who had been switched to RAL and unboosted ATV dual therapy, using data collected during standard-of-care visits.
Results
At 6, 12 and 18 months, viral load was maintained at <400 HIV RNA copies/ml, with only one participant recording a detectable viral load (150 copies/ml) at the 6-month time point. Stable CD4+ T-cell counts were maintained throughout the study period. Five participants changed regimen during the 18-month follow-up, with the median time to switch being 9 months (range 2–12). In three cases, patients were changed from dual therapy because of adverse events while on the regimen. These included increased fatigue (two patients), persistently increased bilirubin (one patient) and gastrointestinal side effects (one patient). Two additional patients changed therapy: one patient added lamivudine and one ceased ATV to pre-empt a potential drug–drug interaction. All five patients who switched from ATV/RAL before 12 months follow-up maintained viral suppression, implying no disadvantage from switching to dual therapy.
Conclusions
Dual therapy with ATV plus RAL maintained viral suppression in this small group of highly ART-experienced patients. Further investigation of this novel dual therapy regimen is warranted.
References
1.
GrinsztejnB., NguyenB.Y., KatlamaC.Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial.Lancet2007; 369: 1261–1269.
2.
WoodR., PhanuphakP., CahnP.Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.J Acquir Immune Defic Syndr2004; 36: 684–692.
3.
MalanD.R., KrantzE., DavidN., WirtzV., HammondJ., McGrathD.Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.J Acquir Immune Defic Syndr2008; 47: 161–167.
4.
KassahunK., McIntoshI., CuiD.Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.Drug Metab Dispos2007; 35: 1657–1663.
5.
ZhangD., ChandoT.J., EverettD.W., PattenC.J., DehalS.S., HumphreysW.G.In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.Drug Metab Dispos2005; 33: 1729–1739.
6.
IwamotoM., WenningL.A., MistryG.C.Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.Clin Infect Dis2008; 47: 137–140.
7.
ZhuL., MahnkeL., ButtertonJ.Pharmacokinetics and safety of twice daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 696.
8.
GuptaS., LatailladeM., FarberS., KozalM.J.Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.J Int Assoc Physicians AIDS Care (Chic Ill)2009; 8: 87–92.
9.
RipamontiD., MaggioloF., BombanaE.Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients.5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract MOPEB067.
10.
WinstonA., BlochM., CarrA.Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.J Antimicrob Chemother2005; 56: 380–387.
11.
HarrisM., LarsenG., MontanerJ.S.Exacerbation of depression associated with starting raltegravir: a report of four cases.AIDS2008; 22: 1890–1892.
